Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Identification of novel targets to improve glioblastoma therapy

Objective

Glioblastoma (GBM) is the most common malignant primary brain tumour in adults. The current standard of care is surgical resection of GBM tumours followed by chemotherapy and ionizing radiation (IR). Despite these intense efforts, GBM tumours remain incurable and the median survival rate of GBM patients remains only ~15 months. This dismal clinical outcome underscores the urgent need for novel therapeutic strategies for GBM. At the cellular level, GBM tumours contain a rare population of self-renewing, highly invasive stem cells termed brain tumour stem cells (BTSCs) that are endowed with properties to proliferate, spur the growth of new tumours, and at the same time, evade IR and chemotherapy. Thus eradicating BTSCs in tumour bulk represents a promising approach to fight brain cancer at its root. However, there are presently no treatments targeting BTSCs in GBM.
Recent preliminary data obtained by the applicant at McGill University (Montreal, Canada) led to the hypothesis that a novel signalling pathway, galectin1/HOXA5, controls BTSC behaviour and represents a promising target to eradicate BTSCs. Thus, the applicant will join the “Laboratoire de l’Angiogenèse et du Microenvironnement des Cancers” at University of Bordeaux to test this hypothesis, under the supervision of Pr. Bikfalvi. The host, the supervisor and the candidate represents the perfect match to realise this proposal and the project is designed to bring forth a two-transfer of knowledge between the host and the candidate. The advanced techniques and transferable skills that the candidate acquires through this research will largely broaden his competencies and increase his employability as an independent researcher in the field of neuro-oncology. Results generated through this proposal will be innovative and of clinical relevance for GBM patients. This study has the potential to open new therapeutic avenues and pave the way for future clinical trials for better treatment of these deadly tumours.

Fields of science

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.

Coordinator

UNIVERSITE DE BORDEAUX
Net EU contribution
€ 211 754,88
Address
PLACE PEY BERLAND 35
33000 Bordeaux
France

See on map

Region
Nouvelle-Aquitaine Aquitaine Gironde
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data